IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. (Nasdaq: INAB) on February 9, 2026, covering events occurring on February 4, 2026. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a leadership appointment within the executive team:
- Appointment: Kate Rochlin, previously the Chief Operating Officer, was appointed as President of the Company.
- Effective Date: February 4, 2026.
- Continued Role: Dr. Rochlin will continue to serve as Chief Operating Officer alongside her new role as President.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It notes that there are no family relationships requiring disclosure under Item 401(d) of Regulation S-K and no transactions requiring disclosure under Item 404(a) of Regulation S-K involving Dr. Rochlin.
Key Facts for Investor Verification
- Verify the dual role of Kate Rochlin as both President and Chief Operating Officer.
- Confirm the effective date of the appointment (February 4, 2026).
- Review the 2025 Proxy Statement (filed April 29, 2025) for Dr. Rochlin's full biographical information.
- Note that this filing does not impact the company's financial statements or capital structure.